IRCT20090127001598N5 IRCT 2020-04-21 Mahan Med Meymeh Kish Clinical validation of Smart Flux hemodialysis filter Clinical validation of Smart Flux hemodialysis filter made by Medica s.p.a company (Italy) with hollow fiber M-PES model, belongs to Mahan Med Meymeh Kish Company, in hemodialysis patients. 2019-05-22 anticipated 40 Complete https://irct.ir/trial/42002 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Used, Assignment: Crossover, Purpose: Treatment, Randomization description: For this purpose, we will use the Quadratic Block Randomization method. For this purpose, we use the numbered list of qualified people from the random number table in the computer system. People in Group I mean " Intervention "and C" are Comparison randomized. Eligible patients were randomly assigned to one of two intervention groups, the smart flux filter or routine filter filter control, based on the number I or C. After the random extraction of the numbers of a block, the above procedure is repeated for four patients. The dose will continue to reach the desired sample size. 3 Hemodialysis adequacy. Intervention 1: Intervention group: Hemodialysis filter with smart flux brand from Italy Medica s.p.a with halofiber model M-PES-1.5 low and high flux from Mahan Med Meymah Kish will be used for dialysis.Each patient in this group is hemodialysed with this type of filter for two weeks (6 sessions). Intervention 2: Control group: In the comparison or control group, patients are hemodialyzed with approved filters (including meditechsys PS16 and 160 filters based on the type of filters studied using equivalent filters). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It should be decided in our institutional ethics committee.